Navigation Links
Combined Molecular-targeted and Hormonal Therapies Offer Promise in Treating Ovarian Cancer

A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors, says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option.

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life, says Dr. Fu. After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation.


'"/>




Page: 1

Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Heart Pill-developed by Dr. Reddy’
8. A Combined Research for Producing Chlamydia Vaccine Begins
9. Combined Ingredients may Cut Cholesterol Levels
10. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
11. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products ... six circular design challenges scheduled to run through early 2018. The challenges are presented ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SC&H Group, ... firm as a Principal in its IT Advisory Services practice . Rossi is ... months as market demand for strategic IT guidance grows, and the practice continues to ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... to visualize, detect, and eliminate cyber threats in real-time, today announced a strategic ... provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... families from two offices in Tyler, has announced the latest beneficiary of their ... Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 According to a new market research report "Neural Network ... Software), Vertical, and Region - Global Forecast to 2021" published by MarketsandMarkets, the ... by 2021, at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... MarketsandMarkets Logo ...
(Date:1/17/2017)... and KANSAS CITY, Mo. ... Hospitals Neonatal Consortium (CHNC) has selected Velos and ... visionary data management and multicenter initiatives. ... comprised of 32 Neonatal Intensive Care Units at ... . The consortium provides a benchmark of ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
Breaking Medicine Technology: